Different genetic mutations in circulating tumor cells were seen between the group receiving fulvestrant and palbociclib and the group just receiving fulvestrant, revealing that different mechanisms are needed to grow in the presence of antiestrogens versus what is needed to bypass CDK4/6 inhibitors. Here, CDK4 is linked to neoplasm.